Gilde Healthcare Partners BV has raised €250 million for its fourth life science fund that targets investments in medical devices, digital health technology and therapeutics in Europe and North America. Koninklijke Philips NV acted as a cornerstone investor.
Vedanta Bioscience Inc has raised $50 million in equity finance to advance candidate therapies targeting the human microbiome for the treatment of infectious and autoimmune diseases.
Ablynx NV, a Belgian developer of antibody fragments originating in llamas, has raised €74.2 million with a private placement of new shares.
Novacyt SA, a listed French cellular diagnostics company, has raised €1.4 million from a private equity placement in order to help finance the expansion of its recently acquired UK company Primerdesign, which has technology for analysing bacteria and viruses.
Shire Plc completed its acquisition of Baxalta Inc on 3 June to create a global company focused on developing drugs for rare diseases and other specialised conditions. The $32 billion deal comprises payments in both cash and Shire equity.
Ryboquin Ltd, a virtual Scottish company with no salaried employees, has raised £1.3 million for the scaling up production of its lead product, Ryboquin ECP-102, which boosts the effectiveness of chemotherapy in cancer patients.
Nouscom SA, a new developer of cancer vaccines raised €12 million in a Series A financing round earlier this month to support the development of a portfolio of products based on oncolytic viruses and viral vectors. The company is based in Basel, Switzerland.
The European Medicines Agency has given positive opinions to two new combination drugs to treat chronic hepatitis C virus (HCV) infection, both of which directly target proteins that cause the virus to replicate in humans.
AstraZeneca Plc has received a complete response letter (CRL) from the US Food and Drug Administration rejecting its application to market a new drug for hyperkalaemia called ZS-9. The CRL relates to an unspecified manufacturing issue.
Aleva Neurotherapeutics SA, a Swiss company with a candidate device for deep brain stimulation, has obtained $18 million in Series C financing enabling it to prepare for the registration of its product in Europe in 2017.